Second Quarter 2022 Financial Results

August 3rd, 2022



moderna

Forward-looking statements and disclaimer

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: anticipated sales, including the timing of sales, under advance purchase agreements in 2022 and the associated dollar amounts to be received, which should not be construed as expected 2022 revenue; the timing of data from proof-of-concept studies in rare diseases and immuno-oncology; the repurchase by Moderna of shares of its common stock under its repurchase programs; the ability of mRNA-1273.214 to induce higher neutralizing antibody titers against Omicron subvariants BA.4/5 when compared to the currently authorized booster; COVID market dynamics and Moderna's ability to meet market needs for fall booster season and the timing for deliveries of fall boosters; potential accelerated approval of mRNA-1010 (flu); the timing of the Company's Phase 1 trial of its combination COVID + flu + RSV vaccine candidate; the ability of the Moderna COVID-19 Vaccine to provide protection against COVID-19 over time, including against evolving variants of concern; Moderna's expectations regarding the evolution of SARS-CoV-2 and the timing for a transition into an endemic phase; Moderna's preparations for commercial sales in 2023; capital allocation; Moderna's 2022 financial framework; Moderna's global public health strategy; and Moderna's goal to achieve net-zero carbon emissions globally by 2030. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, each filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this presentation.

2Q22 earnings call agenda

1. **Business Review – Stéphane Bancel, CEO**
2. Spikevax® COVID-19 Vaccine – Paul Burton, M.D., Ph.D., CMO
3. R&D/Clinical Programs – Stephen Hoge, M.D., President
4. Commercial Market – Arpa Garay, CCO
5. Financials – David Meline, CFO
6. Looking Forward – Stéphane Bancel, CEO

Financial highlights 2Q22

Second quarter 2022 GAAP financial results

- Revenue: $4.7 billion (+9% YoY)
- Net income: $2.2 billion (-21% YoY)
- Continued reduction in shares outstanding in 2Q22
  - 2Q22: Repurchased 9 million shares for $1.3 billion (average price of $142)
  - Total of 18 million shares repurchased since first share repurchase program initially put in place in 2021 (4Q21 to 08/02/22)

2022 outlook

- Reiterating advance purchase agreements for expected delivery in 2022 of ~$21 billion
- Announcing new share repurchase program for an additional $3 billion

moderna

Business updates and pipeline advances

COVID Booster Commercial Updates

- New **supply contract with the U.S. government** for 70 million doses (option for 4 million pediatric doses exercised) with options to purchase an additional 230 million doses
- **Canada and UK** exercised options for 2H22 (now included in $21 billion 2022 APAs)

Pipeline Advances

- **Four programs in Phase 3**
- **Flu (mRNA-1010)** Phase 3 immunogenecity study started
- **Flu (mRNA-1020/-30)** Phase 1/2 trial fully enrolled
- **COVID + Flu** Phase 1/2 trial fully enrolled
- Open IND for **checkpoint vaccine program**
- First patient dosed in **GSDA1 program**

Spikevax Adolescent/ Pediatric Authorizations

- Authorization received from the **U.S. FDA** (6 months to 17 years old)
- **Health Canada** authorization and **Therapeutics Goods Administration (Australia)** conditional approval received (6 months to 5 years)

Data Readouts from Proof-of-Concept Studies in 2H22

- Phase 1/2 data from **propionic acidemia (PA) program** expected in '22
- Phase 2, randomized, data from **personalized cancer vaccine (PCV) program** expected in 4Q22

Moderna as of August 2022

Pipeline

Commercial
Moderna COVID-19 Vaccine/Spikevax®

Phase 3
COVID boosters, Flu, RSV, CMV

Phase 2
Zika, PCV, VEGF-A

46 development programs

Programs in development

Respiratory vaccines
- **COVID variant boosters (variant-specific and bivalents)** in Phase 2/3
- **Older adults RSV** in Phase 3; **Pediatric RSV** in Phase 1
- **Flu (mRNA-1010)** in Phase 3; **Flu (mRNA-1020/-30)** in Phase 1/2
- **Flu + COVID** in Phase 1/2
- **hMPV + PIV3** in Phase 1b age de-escalation study
- **Flu + COVID + RSV, RSV + hMPV, Endemic HCoV** in preclinical

Latent vaccines
- **CMV** in Phase 3
- **EBV, HIV** in Phase 1
- **HSV**, **VZV** in preclinical

Public health vaccines
- **Zika** in Phase 2
- **Nipah** in Phase 1

mRNA therapeutics
14 medicines in 4 therapeutic areas

- **5 Immuno-Oncology**: PCV in Phase 2; KRAS, Triplet, IL-12, checkpoint open IND
- **6 Rare Diseases**: PA, MMA, GSD1a in Phase 1/2; PKU, CN-1, CF in preclinical
- **2 Cardiovascular Diseases**: VEGF-A in Phase 2; Relaxin in preclinical
- **1 Autoimmune Diseases**: PD-L1 in preclinical

Foundations

~3,400
employees[1]

Science 2021 TOP EMPLOYER

7th
Consecutive year top employer by *Science*

11 commercial
subsidiaries across North America, Europe and Asia Pacific

~$18.1B
of cash and investments (unaudited)[1,2]

1. As of June 30, 2022
2. Cash and investments denotes cash, cash equivalents and investments

moderna

2Q22 earnings call agenda

1. Business Review – Stéphane Bancel, CEO
2. **Spikevax® COVID-19 Vaccine – Paul Burton, M.D., Ph.D., CMO**
3. R&D/Clinical Programs – Stephen Hoge, M.D., President
4. Commercial Market – Arpa Garay, CCO
5. Financials – David Meline, CFO
6. Looking Forward – Stéphane Bancel, CEO

Boosting with mRNA-1273 provides substantial protection against COVID-19 infection and hospitalization

3,111,159 matched pairs in Spanish nationwide registry between January 3 – February 6, 2022



"**Estimated effectiveness was 52.5% (51.3–53.7) for an mRNA-1273 booster and 46.2% (43.5–48.7) for a BNT162b2 booster**.... Estimated effectiveness was higher for mRNA-1273 compared with BNT162b2 and increased with time between completed primary vaccination and booster."

Monge S et al., Lancet Infect Dis. 2022 Jun 2:S1473-3099(22)00292-4. https://doi.org/10.1016/S1473-3099(22)00292-4

Boosting with mRNA-1273 provides substantial protection against COVID-19 infection and hospitalization

462,950 booster recipients September – December 2021 in U.S. Veteran Affairs Medical Center study



"[Relative vaccine effectiveness] (95% CI) was 19% (17-22%) for confirmed infection, **52% (46-57%) for hospitalization, and 83% (65-92%) for ICU admission or death.** Recipients of the mRNA-1273 vaccine had a lower cumulative incidence of infections and hospitalizations compared with BNT-162b2 vaccine (log-rank p-value p<0.001 for both comparisons)."

Butt AA, et al., Clin Infect Dis. 2022 May 3:ciac328. https://doi.org/10.1093/cid/ciac328

Boosting with mRNA-1273 provides substantial protection against COVID-19 infection and hospitalization

3,056,862 matched pairs in NHS England between October 29, 2021 and January 31, 2022

COVID-19 Hospitalization, cumulative incidence/1000



"Booster vaccination with **mRNA-1273 COVID-19 vaccine was more effective than BNT162b2** in preventing SARS-CoV-2 infection and COVID-19 hospitalisation during the first 12 weeks after vaccination, during a period of **Delta followed by Omicron variant dominance.**"

https://www.medrxiv.org/content/10.1101/2022.07.29.22278186v1.full.pdf
Peer review of study is pending

disCOVEries study: Innovative, decentralized trial designed to compare Pfizer vs. Moderna antibody levels

- Real-world **assessment of antibody levels**
  - Used mobile health technology to recruit/enroll participants and at-home blood collection self-conducted by participants
- The study was **designed to compare, head-to-head** Pfizer-Pfizer-Pfizer (PPP) vs. Moderna-Moderna-Moderna (MMM) antibody levels
- Observational, prospective 3-month study
- Enrolled ~850 participants
  - 60% female, 47% reporting as Asian, Black or African American, Hispanic or Latino and average age of 44



https://www.medrxiv.org/content/10.1101/2022.07.31.22278173v1
Peer review of study is pending

Results show higher antibody levels with MMM vs. PPP for ancestral virus and variants of concern

- **Primary endpoint**: Antibody level since receiving a COVID-19 booster (each participant providing 3 total samples at approximately 0-, 1-, and 2- months post-enrollment)
- Results shows **higher antibody levels with MMM vs. PPP** for variants of concerns

Antibody GMTs and GMRs From ≥8 Weeks Through ≥32 Weeks Following First Booster in the MMM and PPP Cohorts



**** P<0.001 for significance*

GMTs and corresponding 95% CIs were based on raw data without model adjustment and were plotted over time for the MMM and PPP vaccine/booster series arms. The number displayed above each GMT represents the GMR when comparing MMM vs PPP, calculated from the ANCOVA model

https://www.medrxiv.org/content/10.1101/2022.07.31.22278173v1
Peer review of study is pending

Results show higher antibody levels with MMM vs. PPP for Omicron BA.1

- Results show **higher antibody levels with MMM vs. PPP** for Omicron BA.1 and better durability
  - Moderna titer levels at 24-28 weeks equal to Pfizer titer levels at 12-16 weeks

Antibody GMTs and GMRs From ≥8 Weeks Through ≥32 Weeks Following First Booster in the MMM and PPP Cohorts



*** P<0.001 for significance

https://www.medrxiv.org/content/10.1101/2022.07.31.22278173v1
Peer review of study is pending

2Q22 earnings call agenda

1. Business Review – Stéphane Bancel, CEO
2. Spikevax® COVID-19 Vaccine – Paul Burton, M.D., Ph.D., CMO
3. **R&D/Clinical Programs – Stephen Hoge, M.D., President**
4. Commercial Market – Arpa Garay, CCO
5. Financials – David Meline, CFO
6. Looking Forward – Stéphane Bancel, CEO

We are advancing two bivalent candidates for the fall to meet different market needs

mRNA-1273.214

(25 µg of mRNA-1273 and 25 µg of Omicron BA.1)

- Demonstrated significantly higher titers against the BA.4/5 strain in a clinical trial before the fall booster season, when compared to the currently authorized booster

mRNA-1273.222

(25 µg of mRNA-1273 and 25 µg of Omicron BA.4/5)

- Based on the BA.4/5 strain and is being developed consistent with recent FDA advice

Respiratory vaccines: Flu, RSV vaccines ongoing in Phase 3 studies

- **COVID-19 variant boosters and next generation booster (mRNA-1283)** in development
- **Flu (mRNA-1010)** Phase 3 safety & immunogenecity trial ongoing to support potential accelerated approval and preparing for Phase 3 efficacy study in fall 2022 (if needed); **Flu (mRNA-1020/-30)** Phase 1/2 trial fully enrolled
- **Older adults RSV** Phase 3, known as ConquerRSV, is ongoing; **Pediatric RSV** in Phase 1
- **Combination COVID + flu (mRNA-1073)** Phase 1/2 fully enrolled
- **Combination COVID + flu + RSV (mRNA-1230)** in preclinical, expected to start Phase 1 trial in 2022; **Endemic HCoV** in preclinical
- **Pediatric hMPV + PIV3** Phase 1b fully enrolled; **Pediatric RSV + hMPV** in preclinical



Latent & public health vaccines: CMV vaccine ongoing in Phase 3 study

- **CMV vaccine** pivotal Phase 3 study, known as CMVictory, is ongoing
- **EBV vaccine (to prevent infectious mononucleosis)** Phase 1 is ongoing; **EBV vaccine (to prevent EBV sequelae)** in preclinical
- **HIV vaccines** Phase 1 trials are ongoing
- **HSV and VZV vaccines** in preclinical
- **Zika vaccine** ongoing in a Phase 2 study
- **Nipah vaccine** Phase 1 study, led by the NIH, is ongoing (first participant dosed in July)

Modality	Program	ID #	Preclinical development	Phase 1	Phase 2	Phase 3	Commercial	Moderna rights
Latent vaccines / Prophylactic vaccines	CMV vaccine	**mRNA-1647**						Worldwide
	EBV vaccine *(to prevent infectious mononucleosis)*	**mRNA-1189**						Worldwide
	EBV vaccine *(to prevent EBV sequelae)*	**mRNA-1195**						Worldwide
	HSV vaccine	**mRNA-1608**						Worldwide
	VZV vaccine	**mRNA-1468**						Worldwide
	HIV vaccines	**mRNA-1644**						Worldwide ***IAVI/others** funded*
		mRNA-1574						Worldwide ***BMGF/NIAID/ others** funded*
Public health vaccines	Zika vaccine	**mRNA-1893**						Worldwide ***BARDA** funded*
	Nipah vaccine	**mRNA-1215**						Worldwide ***NIH** funded*

mRNA therapeutics: Data expected from PA and PCV programs in ’22

Immuno-oncology
- **PCV** Phase 1 ongoing; Phase 2 fully enrolled, data expected in 4Q 2022
- **KRAS** Phase 1 ongoing; evaluating next steps for the program
- **Triplet, IL-12** ongoing in Phase 1
- **Checkpoint vaccine** open IND

Cardiovascular
- **VEGF** After portfolio review AstraZeneca returns program; Moderna evaluating next steps for the program
- **Relaxin** in preclinical

Autoimmune
- **IL-2** stopping after early clinical data and evolving competitive landscape
- **PD-L1** in preclinical

Rare diseases
- **PA** Phase 1/2 cohorts 1 & 2 fully enrolled; enrolling additional cohorts
- **MMA** Phase 1/2 cohort 1 fully enrolled; enrolling additional cohorts
- **GSD1a** Phase 1 trial first patient dosed
- **PKU, CN-1** and **CF** in preclinical



2Q22 earnings call agenda

1. Business Review – Stéphane Bancel, CEO
2. Spikevax® COVID-19 Vaccine – Paul Burton, M.D., Ph.D., CMO
3. R&D/Clinical Programs – Stephen Hoge, M.D., President
4. **Commercial Market – Arpa Garay, CCO**
5. Financials – David Meline, CFO
6. Looking Forward – Stéphane Bancel, CEO

Second quarter 2022 Product Sales of $4.5 billion, $10.5 billion in 1H 2022 (unaudited)

Product Sales YoY Comparison



Q2 2022 Product Sales: $4.5 billion

- North America: $1.6 billion, includes pediatric deliveries
- EMEA: $1.5 billion
- APAC: $1.1 billion
- RoW: $0.4 billion

YTD June 30, 2022, Product Sales: $10.5 billion

- North America: $2.7 billion, includes pediatric deliveries
- EMEA: $3.9 billion
- APAC: $3.0 billion
- RoW: $0.8 billion

moderna

Spikevax® continues to show substantial market share

Booster market in OECD countries continue to be an mRNA vaccine market

Spikevax® Cumulative Booster Market Share



Sources: (Data snapshot was downloaded on 7/20/22 from each country's website (data shown is until 07/13 (US), 06/19 (Canada), 07/10 (EU4), 07/17 (Korea, JP); all the historical data might be restated in the future)

- US: Booster authorized in ages 65+, high-risk individuals on Oct. 20; Booster authorized in ages 18+ on Nov. 19; https://data.cdc.gov/Vaccinations/COVID-19-Vaccinations-in-the-United-States-Jurisdi/unsk-b7fc
- CA: Booster authorized in 18+ years old on Nov. 15, 2021: https://health-infobase.canada.ca/covid-19/vaccine-administration/
- EU: Booster recommended in ages 18+ on Oct. 25; https://www.ecdc.europa.eu/en/publications-data/data-covid-19-vaccination-eu-eea
- SK: Moderna vaccine granted EUA on Oct. 26, 2021; https://ncv.kdca.go.kr/vaccineStatus.es?mid=a11710000000
- JP: Moderna Booster recommended on Dec. 16, 2021; https://www.kantei.go.jp/

Methodology:

- Oct '21 = Cumulative Moderna share of administered 3rd doses 10/3-10/31/21
- Feb '22 = Cumulative Moderna share of administered 3rd doses 10/3/21-2/13/22
- Jul '22 = Cumulative Moderna share of administered Booster doses (3rd and 4th) 10/3/21- mid-July'22 (varies by country), except Canada is until June'19
- Jul '22 Share is calculated for combined Third and Fourth Doses (vast majority is booster; may include doses for immuno-compromised)
- Share is only calculated for doses where manufacturer has been identified in the public data source
- For Italy and Japan, data is not reported for fourth booster dose volumes

New U.S. government contract for fall 2022 COVID booster doses

- New U.S. government contract includes an award up to $1.8 billion for 70 million doses to be delivered in 2022; additional options, if exercised, may raise total to 300 million doses
  - U.S. government exercised option for an additional 4 million pediatric doses (included in the 70 million doses for 2022)

- Doses scheduled for delivery will be the Omicron-adapted bivalent COVID booster (mRNA-1273.222), which consists of wild-type + Omicron BA.4/5 variant

moderna

COVID booster commercial outlook in 2022

ILLUSTRATIVE



Commercial Dynamics

- Moderna is advancing two bivalent candidates for fall 2022 based on different market needs for Omicron subvariants (mRNA-1273.214 and mRNA-1273.222)
- Both bivalent candidates contain 25 µg of the currently authorized booster (mRNA-1273) and 25 µg of an Omicron subvariant(s)
- Deliveries for fall boosters to start in September and will be more heavily weighted in 4Q22 as we scale up manufacturing for bivalent boosters and receive regulatory authorizations
- Moderna's commercial infrastructure is prepared for a 2023 commercial market

2Q22 earnings call agenda

1. Business Review – Stéphane Bancel, CEO
2. Spikevax® COVID-19 Vaccine – Paul Burton, M.D., Ph.D., CMO
3. R&D/Clinical Programs – Stephen Hoge, M.D., President
4. Commercial Market – Arpa Garay, CCO
5. **Financials – David Meline, CFO**
6. Looking Forward – Stéphane Bancel, CEO

Second quarter 2022 financial results

In $ millions, except per share amounts (unaudited)	Q2 2022	Q2 2021	QoQ Change (Q2 22 vs. Q2 21)	
Product sales	**$ 4,531**	**$ 4,197**	**$ 334**	**8 %**
Grant revenue	183	139	44	32 %
Collaboration revenue	35	18	17	94 %
Total revenue	**4,749**	**4,354**	**395**	**9 %**
Cost of sales	1,381	750	631	84 %
Research and development	710	421	289	69 %
Selling, general and administrative	211	121	90	74 %
Total operating expenses	**2,302**	**1,292**	**1,010**	**78 %**
Income from operations	**2,447**	**3,062**	**(615)**	**(20)%**
Other income	27	1	26	NM
Provision for income taxes	277	283	(6)	(2) %
Net income	**$ 2,197**	**$ 2,780**	**$ (583)**	**(21)%**
Earnings per share – Diluted	$ 5.24	$ 6.46	$ (1.22)	(19) %
Weighted average shares – Diluted	419	431	(12)	(3) %
Effective tax rate	11 %	9 %		

Year-to-date 2022 financial results

In $ millions, except per share amounts (unaudited)	2022 YTD ended 6/30/22	2021 YTD ended 6/30/21	YoY Change	
Product sales	**$ 10,456**	**$ 5,930**	**$ 4,526**	**76 %**
Grant revenue	309	333	(24)	(7) %
Collaboration revenue	50	28	22	79 %
Total revenue	**10,815**	**6,291**	**4,524**	**72 %**
Cost of sales	2,398	943	1,455	154 %
Research and development	1,264	822	442	54 %
Selling, general and administrative	479	198	281	142 %
Total operating expenses	**4,141**	**1,963**	**2,178**	**111 %**
Income from operations	**6,674**	**4,328**	**2,346**	**54 %**
Other income (expense)	29	(5)	34	NM
Provision for income taxes	849	322	527	164 %
Net income	**$ 5,854**	**$ 4,001**	**$ 1,853**	**46 %**
Earnings per share – Diluted	$ 13.85	$ 9.30	$ 4.55	49 %
Weighted average shares – Diluted	423	430	(7)	(2) %
Effective tax rate	13 %	7 %		

Cash/ Investments and Cash Deposits (unaudited)



- Cash, Cash equivalents and Investments as of June 30, 2022 at $18.1 billion, down from $19.3 billion as of March 31, 2022

- Balance of Cash deposits for future product supply as of June 30, 2022 at $4.1 billion, below prior quarter driven by product deliveries against customer deposits

Cash and investments decreased, reflecting the share buybacks in Q2

Moderna's capital allocation priorities

1. **Reinvest in the business** & accelerate investment in R&D, manufacturing infrastructure and company buildout

2. **Seek attractive external investment opportunities (licenses and/or M&A)** to further expand the reach of Moderna's technology

3. **Return capital to shareholders**

Share buyback details

Share buybacks:

- **Q2 2022: 9 million shares** for $1.3 billion
- **Cumulative buybacks to date**: **18 million shares** (~4% of outstanding diluted shares) for $3 billion

- Announced $3 billion share buyback program in February 2022 **with approximately $1 billion remaining capacity as of today**
- **Announcing approval of a new $3 billion share buyback program** in August 2022, with no expiry

2022 updated financial framework

Sales	▪ **Advance purchase agreements** (APAs) for **expected delivery in 2022 of ~$21 billion** of product sales, reflecting new US government contract for 2022 and a downward adjustment for COVAX doses ▪ We **expect sales to be higher in Q4 than in Q3**, driven by the timing of authorizations and regulatory approvals of our updated COVID vaccines
Cost of sales	▪ We now **expect full year 2022 reported cost of sales in the mid-20s percentage range**, with possible high-20s in the event of further charges due to product updates
R&D and SG&A Expenses	▪ We continue to **expect full year R&D and SG&A expenses of ~$4 billion**
Tax rate	▪ We now **expect an Effective Tax Rate for the full year in the low- to mid-teen percentage range**
Capital Expenditures	▪ We continue to **expect capital expenditures in the range of $0.6-$0.8 billion**

2Q22 earnings call agenda

1. Business Review – Stéphane Bancel, CEO
2. Spikevax® COVID-19 Vaccine – Paul Burton, M.D., Ph.D., CMO
3. R&D/Clinical Programs – Stephen Hoge, M.D., President
4. Commercial Market – Arpa Garay, CCO
5. Financials – David Meline, CFO
6. **Looking Forward – Stéphane Bancel, CEO**

Moderna's 2022 priorities

1. Execute on $21B signed APAs and deliver fall boosters
2. Execute on late-stage clinical vaccine pipeline with flu, RSV, and CMV Phase 3 trials
3. Advance therapeutic programs and share proof-of-concept readouts for our PA and PCV programs
4. Bring forward more mRNA candidates into development
5. Expand our mRNA platform

Published first ESG report in June

Select highlights:

- **Medicines for patients:** Announced global public health strategy including goal to target 15 priority pathogens by 2025 and mRNA access collaborative
- **Employees**: Continued workforce growth with focus on talent and creating a culture of inclusion and belonging
- **Environment**: Goal to achieve net-zero carbon emissions globally by 2030 (will share 2021 baseline data after third party verification)
- **Community**: Launched the Moderna Charitable Foundation
- **Governance & ethics**: Continue to evolve ESG governance, commitment to transparency in clinical trials and political engagement, and reporting under SASB framework



https://assets.modernatx.com/m/ccaae809ca9152c/original/Moderna_ESG_2021.pdf



Save the Date
Events in 2022

R&D Day
September 8th

ESG Day
November 10th

Our mission

To deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.

Moderna's Respiratory Vaccines (Pipeline 1/3)

Modality	Program	ID #	Preclinical development / Phase 1 / Phase 2 / Phase 3 / Commercial	Moderna rights
Adults — Prophylactic vaccines	COVID-19 vaccine	**mRNA-1273/Spikevax®**		Worldwide
		mRNA-1273.214	Omicron (BA.1) variant + wild-type	Worldwide
		mRNA-1273.222	Omicron (BA.4/5) variant + wild-type	Worldwide
		mRNA-1273.529	Omicron (BA.1) variant	Worldwide
		mRNA-1273.351	Beta variant	Worldwide
		mRNA-1273.617	Delta variant	Worldwide
		mRNA-1273.211	Beta variant + wild-type	Worldwide
		mRNA-1273.213	Beta + Delta variant	Worldwide
		mRNA-1283	Next generation (2-5 °C)	Worldwide
	Flu vaccine	**mRNA-1010**		Worldwide
		mRNA-1020		Worldwide
		mRNA-1030		Worldwide
		mRNA-1011		Worldwide
		mRNA-1012		Worldwide
	Older adults RSV vaccine	**mRNA-1345**		Worldwide
	COVID + Flu vaccine	**mRNA-1073**		Worldwide
	COVID + Flu + RSV vaccine	**mRNA-1230**		Worldwide
	Endemic HCoV vaccine	**mRNA-1287**		Worldwide
Adolescents & Pediatrics	COVID-19 vaccine (adolescents)	**mRNA-1273/Spikevax®**	TeenCOVE	Worldwide
	COVID-19 vaccine (pediatrics)	**mRNA-1273/Spikevax®**	KidCOVE	Worldwide
	Pediatric RSV vaccine	**mRNA-1345**		Worldwide
	Pediatric hMPV + PIV3 vaccine	**mRNA-1653**		Worldwide
	Pediatric RSV + hMPV vaccine	**mRNA-1365**		Worldwide

Moderna's Latent & Public Health Vaccines (Pipeline 2/3)

Modality	Program	ID #	Preclinical development	Phase 1	Phase 2	Phase 3	Commercial	Moderna rights
Latent vaccines	CMV vaccine	**mRNA-1647**						Worldwide
	EBV vaccine *(to prevent infectious mononucleosis)*	**mRNA-1189**						Worldwide
	EBV vaccine *(to prevent EBV sequelae)*	**mRNA-1195**						Worldwide
Prophylactic vaccines	HSV vaccine	**mRNA-1608**						Worldwide
	VZV vaccine	**mRNA-1468**						Worldwide
	HIV vaccines	**mRNA-1644**						Worldwide ***IAVI/others*** *funded*
		mRNA-1574						Worldwide ***BMGF/NIAID/ others*** *funded*
Public health vaccines	Zika vaccine	**mRNA-1893**						Worldwide ***BARDA*** *funded*
	Nipah vaccine	**mRNA-1215**						Worldwide ***NIH*** *funded*

Moderna's Therapeutics (Pipeline 3/3)

Modality	Program	ID #	Preclinical development	Phase 1	Phase 2	Phase 3	Commercial	Moderna rights
Systemic secreted & cell surface therapeutics	Relaxin *Heart failure*	**mRNA-0184**						Worldwide
	PD-L1 *Autoimmune hepatitis*	**mRNA-6981**						Worldwide
	Personalized cancer vaccine (PCV)	**mRNA-4157**						50-50 global profit sharing with **Merck**
Cancer vaccines	KRAS vaccine	**mRNA-4671**						Worldwide
	Checkpoint vaccine	**mRNA-4359**	Open IND					Worldwide
Intratumoral Immuno-oncology	OX40L/IL-23/IL-36γ (Triplet) *Solid tumors/lymphoma*	**mRNA-2752**						Worldwide
	IL-12 *Solid tumors*	**MEDI1191**						50-50 U.S. profit sharing; **AZ** to pay royalties on ex-U.S. sales
Localized Regenerative Therapeutics	VEGF-A *Myocardial ischemia*	**AZD8601**						Worldwide
	Propionic acidemia (PA)	**mRNA-3927**						Worldwide
	Methylmalonic acidemia (MMA)	**mRNA-3705**						Worldwide
Systemic Intracellular Therapeutics	Glycogen storage disease type 1a (GSD1a)	**mRNA-3745**						Worldwide
	Phenylketonuria (PKU)	**mRNA-3283**						Worldwide
Inhaled Pulmonary Therapeutics	Crigler-Najjar syndrome type 1 (CN-1)	**mRNA-3351**						Provided to **ILCM** free of charge
	Cystic fibrosis (CF)	**VXc-522**						**Vertex** to pay milestones and royalties